{"success":true,"data":{"pressRelease":{"id":"168393","rtpr_id":"nPn6GxL3Ba-20261014","ticker":"DHR","exchange":"NYSE","all_tickers":["DHR"],"title":"Danaher Collaborates with NVIDIA to Advance Autonomous Science","author":"PR Newswire","published_at":"2026-10-14T06:00:01.085Z","article_body":"Danaher Collaborates with NVIDIA to Advance Autonomous Science\nPR Newswire\n\nWASHINGTON, Oct. 14, 2026\n\nCollaboration will bring together NVIDIA AI technologies and Danaher's\nscientific instruments, laboratory workflows and data\n\nWASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR)\ntoday announced a collaboration with NVIDIA to advance autonomous science and\nhelp accelerate the pace of scientific discovery. As part of Danaher's broader\neffort to shape the future of AI-enabled science, the companies are working to\ncombine Danaher's scientific instrumentation, automation technologies,\nlaboratory workflow software and domain expertise with NVIDIA accelerated\ncomputing and AI technologies. The goal is to help researchers move faster\nfrom prediction to experimental evidence, creating a continuous learning cycle\nwhere experiments inform models and models help design better experiments.\n\n\"AI is reshaping how science is conducted, and Danaher is at the forefront of\nthat transformation,\" said Julie Sawyer Montgomery, President and Chief\nExecutive Officer of Danaher. \"We are collaborating around a shared vision for\nmore connected, adaptive and accessible innovation, helping researchers solve\nconsequential challenges and translate discovery into human impact.\"\n\n\"The next era of scientific discovery will be driven by a continuous loop\nbetween AI and experimentation,\" said Kimberly Powell, Vice President of\nHealthcare at NVIDIA. \"Together with Danaher, we are bringing accelerated\ncomputing and physical AI into the lab - connecting models with instruments\nand real experimental data, where experiments improve models and models design\nbetter experiments, helping researchers compress years of discovery into\nmonths.\"\n\nDanaher and NVIDIA are working to integrate AI into scientific instruments\nthrough edge computing like NVIDIA DGX Spark, accelerated analytics and data\nprocessing with RAPIDS, real-time inference, scientific reasoning and\nfoundation model technologies, including BioNeMo Open Models. Initial efforts\nfocus on a select group of priority instruments, with the potential to expand\nacross a broader portfolio over time. The companies are exploring how\nscientific and physical AI, such as NVIDIA Cosmos world models and Omniverse\nDigital Twins, can support more intelligent instruments and laboratory\nworkflows, while keeping experimental evidence at the center of scientific\ndecision-making.\n\nThe collaboration seeks to advance Danaher's commitment to connected science\nby bringing AI, accelerated computing, instruments, workflows and experimental\ndata together to produce experimental evidence. Danaher aims to help\nresearchers reduce the time and complexity of moving from an AI-generated\nprediction to the experimental evidence needed to act on it, while preserving\ncustomer choice in models, standards and technology providers.\n\nFORWARD-LOOKING STATEMENTS AND OTHER INFORMATION\nStatements in this release that are not strictly historical, including\nstatements regarding the collaboration between Danaher and NVIDIA, the\nanticipated scope, timing, expansion, capabilities and benefits of the\ncollaboration, the integration of AI technologies into scientific instruments\nand laboratory workflows, the expected development and deployment of\nAI-enabled scientific solutions, and the anticipated impact of these\ntechnologies on scientific research and discovery, and any other statements\nregarding events or developments that we believe or anticipate will or may\noccur in the future are \"forward-looking\" statements within the meaning of the\nfederal securities laws. There are a number of important factors that could\ncause actual results, developments and business decisions to differ materially\nfrom those suggested or indicated by such forward-looking statements and you\nshould not place undue reliance on any such forward-looking statements. These\nfactors include, among other things: the impact of the tariffs and related\nactions implemented by the U.S. and other countries, the impact of our debt\nobligations (including debt we have incurred to finance the acquisition of\nMasimo Corporation) on our operations and liquidity, deterioration of or\ninstability in the global economy, the markets we serve and the financial\nmarkets, uncertainties with respect to the development, deployment, and use of\nartificial intelligence in our business and products, the impact of global\nhealth crises, uncertainties relating to national laws or policies, including\nlaws or policies to protect or promote domestic interests and/or address\nforeign competition, our ability to successfully identify and consummate\nappropriate acquisitions and strategic investments, our ability to integrate\nthe businesses we acquire and achieve the anticipated growth, synergies and\nother benefits of such acquisitions, contingent liabilities and other risks\nrelating to acquisitions, investments, strategic relationships and\ndivestitures (in each case, including with respect to our acquisition of\nMasimo), including tax-related and other contingent liabilities relating to\npast and future IPOs, split-offs or spin-offs, contractions or growth rates\nand cyclicality of markets we serve, competition, our ability to develop and\nsuccessfully market new products and technologies and expand into new markets,\nthe potential for improper conduct by our employees, agents or business\npartners, our compliance with applicable laws and regulations (including rules\nrelating to off-label marketing and other regulations relating to medical\ndevices and the health care industry), the results of our clinical trials and\nperceptions thereof, our ability to effectively address cost reductions and\nother changes in the health care industry, security breaches or other\ndisruptions of our information technology systems or violations of data\nprivacy laws, risks relating to potential impairment of goodwill and other\nintangible assets, currency exchange rates, tax audits and changes in our tax\nrate and income tax liabilities, changes in tax laws applicable to\nmultinational companies, litigation, regulatory proceedings and other\ncontingent liabilities including intellectual property and environmental,\nhealth and safety matters, the rights of the United States government with\nrespect to our production capacity in times of national emergency or with\nrespect to intellectual property/production capacity developed using\ngovernment funding, risks relating to product, service or software defects,\nproduct liability and recalls, risks relating to our manufacturing operations,\nthe impact of climate change, legal or regulatory measures to address climate\nchange and other sustainability topics and our ability to address regulatory\nrequirements or stakeholder expectations relating to climate change and other\nsustainability topics, risks relating to fluctuations in the cost and\navailability of the supplies we use (including commodities) and labor we need\nfor our operations, our relationships with and the performance of our channel\npartners, uncertainties relating to collaboration arrangements with\nthird-parties, the impact of deregulation on demand for our products and\nservices, labor matters and our ability to recruit, retain and motivate\ntalented employees, U.S. and non-U.S. economic, political, geopolitical,\nlegal, compliance, social and business factors (including the impact of\nelections, regulatory and policy changes or uncertainty, government shutdowns\nand military conflicts such as the conflict in the Middle East), disruptions\nand other impacts relating to man-made and natural disasters, inflation and\nthe impact of our By-law exclusive forum provisions. Additional information\nregarding the factors that may cause actual results to differ materially from\nthese forward-looking statements is available in our SEC filings, including\nour 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the\nsecond quarter of 2026. These forward-looking statements speak only as of the\ndate of this release and except to the extent required by applicable law, the\nCompany does not assume any obligation to update or revise any forward-looking\nstatement, whether as a result of new information, future events and\ndevelopments or otherwise.\n\nABOUT DANAHER\nDanaher is a leading global life sciences and diagnostics innovator, committed\nto advancing the power of science and technology to improve human health.\nThrough our connected ecosystem of industry-leading businesses, we work side\nby side with customers to solve many of their most complex scientific and\nclinical challenges—accelerating the moment scientific discovery becomes\nhuman impact. Powered by the Danaher Business System, our advanced science and\ntechnology and proven ability to innovate help enable faster, more accurate\ndiagnoses and reduce the time, cost, and risk required to discover, develop,\nand deliver life-changing therapies. Through continuous improvement and\noperational excellence, our approximately 60,000 associates worldwide are\nfocused on delivering lasting impact and improving quality of life around the\nworld, while building a healthier, more sustainable tomorrow. That's\nInnovation at the speed of life. Explore more at www.danaher.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796774-1&h=452825110&u=http%3A%2F%2Fwww.danaher.com%2F&a=www.danaher.com)\n.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/danaher-collaborates-with-nvidia-to-advance-autonomous-science-302907891.html\n(https://www.prnewswire.com/news-releases/danaher-collaborates-with-nvidia-to-advance-autonomous-science-302907891.html)\n\nSOURCE Danaher Corporation\n\n\n\nInvestor: Rachel Vatnsdal, Vice President, Investor Relations, investor.relations@danaher.com; Media: Mary Kathryn Steel, Vice President, Corporate Communications, media@danaher.com; Danaher Corporate, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn6GxL3Ba-20261014","title":"Danaher Collaborates with NVIDIA to Advance Autonomous Science","author":"PR Newswire","ticker":"DHR","created":"2026-10-14T06:00:01.085Z","tickers":["DHR"],"exchange":"NYSE","article_body":"Danaher Collaborates with NVIDIA to Advance Autonomous Science\nPR Newswire\n\nWASHINGTON, Oct. 14, 2026\n\nCollaboration will bring together NVIDIA AI technologies and Danaher's\nscientific instruments, laboratory workflows and data\n\nWASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR)\ntoday announced a collaboration with NVIDIA to advance autonomous science and\nhelp accelerate the pace of scientific discovery. As part of Danaher's broader\neffort to shape the future of AI-enabled science, the companies are working to\ncombine Danaher's scientific instrumentation, automation technologies,\nlaboratory workflow software and domain expertise with NVIDIA accelerated\ncomputing and AI technologies. The goal is to help researchers move faster\nfrom prediction to experimental evidence, creating a continuous learning cycle\nwhere experiments inform models and models help design better experiments.\n\n\"AI is reshaping how science is conducted, and Danaher is at the forefront of\nthat transformation,\" said Julie Sawyer Montgomery, President and Chief\nExecutive Officer of Danaher. \"We are collaborating around a shared vision for\nmore connected, adaptive and accessible innovation, helping researchers solve\nconsequential challenges and translate discovery into human impact.\"\n\n\"The next era of scientific discovery will be driven by a continuous loop\nbetween AI and experimentation,\" said Kimberly Powell, Vice President of\nHealthcare at NVIDIA. \"Together with Danaher, we are bringing accelerated\ncomputing and physical AI into the lab - connecting models with instruments\nand real experimental data, where experiments improve models and models design\nbetter experiments, helping researchers compress years of discovery into\nmonths.\"\n\nDanaher and NVIDIA are working to integrate AI into scientific instruments\nthrough edge computing like NVIDIA DGX Spark, accelerated analytics and data\nprocessing with RAPIDS, real-time inference, scientific reasoning and\nfoundation model technologies, including BioNeMo Open Models. Initial efforts\nfocus on a select group of priority instruments, with the potential to expand\nacross a broader portfolio over time. The companies are exploring how\nscientific and physical AI, such as NVIDIA Cosmos world models and Omniverse\nDigital Twins, can support more intelligent instruments and laboratory\nworkflows, while keeping experimental evidence at the center of scientific\ndecision-making.\n\nThe collaboration seeks to advance Danaher's commitment to connected science\nby bringing AI, accelerated computing, instruments, workflows and experimental\ndata together to produce experimental evidence. Danaher aims to help\nresearchers reduce the time and complexity of moving from an AI-generated\nprediction to the experimental evidence needed to act on it, while preserving\ncustomer choice in models, standards and technology providers.\n\nFORWARD-LOOKING STATEMENTS AND OTHER INFORMATION\nStatements in this release that are not strictly historical, including\nstatements regarding the collaboration between Danaher and NVIDIA, the\nanticipated scope, timing, expansion, capabilities and benefits of the\ncollaboration, the integration of AI technologies into scientific instruments\nand laboratory workflows, the expected development and deployment of\nAI-enabled scientific solutions, and the anticipated impact of these\ntechnologies on scientific research and discovery, and any other statements\nregarding events or developments that we believe or anticipate will or may\noccur in the future are \"forward-looking\" statements within the meaning of the\nfederal securities laws. There are a number of important factors that could\ncause actual results, developments and business decisions to differ materially\nfrom those suggested or indicated by such forward-looking statements and you\nshould not place undue reliance on any such forward-looking statements. These\nfactors include, among other things: the impact of the tariffs and related\nactions implemented by the U.S. and other countries, the impact of our debt\nobligations (including debt we have incurred to finance the acquisition of\nMasimo Corporation) on our operations and liquidity, deterioration of or\ninstability in the global economy, the markets we serve and the financial\nmarkets, uncertainties with respect to the development, deployment, and use of\nartificial intelligence in our business and products, the impact of global\nhealth crises, uncertainties relating to national laws or policies, including\nlaws or policies to protect or promote domestic interests and/or address\nforeign competition, our ability to successfully identify and consummate\nappropriate acquisitions and strategic investments, our ability to integrate\nthe businesses we acquire and achieve the anticipated growth, synergies and\nother benefits of such acquisitions, contingent liabilities and other risks\nrelating to acquisitions, investments, strategic relationships and\ndivestitures (in each case, including with respect to our acquisition of\nMasimo), including tax-related and other contingent liabilities relating to\npast and future IPOs, split-offs or spin-offs, contractions or growth rates\nand cyclicality of markets we serve, competition, our ability to develop and\nsuccessfully market new products and technologies and expand into new markets,\nthe potential for improper conduct by our employees, agents or business\npartners, our compliance with applicable laws and regulations (including rules\nrelating to off-label marketing and other regulations relating to medical\ndevices and the health care industry), the results of our clinical trials and\nperceptions thereof, our ability to effectively address cost reductions and\nother changes in the health care industry, security breaches or other\ndisruptions of our information technology systems or violations of data\nprivacy laws, risks relating to potential impairment of goodwill and other\nintangible assets, currency exchange rates, tax audits and changes in our tax\nrate and income tax liabilities, changes in tax laws applicable to\nmultinational companies, litigation, regulatory proceedings and other\ncontingent liabilities including intellectual property and environmental,\nhealth and safety matters, the rights of the United States government with\nrespect to our production capacity in times of national emergency or with\nrespect to intellectual property/production capacity developed using\ngovernment funding, risks relating to product, service or software defects,\nproduct liability and recalls, risks relating to our manufacturing operations,\nthe impact of climate change, legal or regulatory measures to address climate\nchange and other sustainability topics and our ability to address regulatory\nrequirements or stakeholder expectations relating to climate change and other\nsustainability topics, risks relating to fluctuations in the cost and\navailability of the supplies we use (including commodities) and labor we need\nfor our operations, our relationships with and the performance of our channel\npartners, uncertainties relating to collaboration arrangements with\nthird-parties, the impact of deregulation on demand for our products and\nservices, labor matters and our ability to recruit, retain and motivate\ntalented employees, U.S. and non-U.S. economic, political, geopolitical,\nlegal, compliance, social and business factors (including the impact of\nelections, regulatory and policy changes or uncertainty, government shutdowns\nand military conflicts such as the conflict in the Middle East), disruptions\nand other impacts relating to man-made and natural disasters, inflation and\nthe impact of our By-law exclusive forum provisions. Additional information\nregarding the factors that may cause actual results to differ materially from\nthese forward-looking statements is available in our SEC filings, including\nour 2025 Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the\nsecond quarter of 2026. These forward-looking statements speak only as of the\ndate of this release and except to the extent required by applicable law, the\nCompany does not assume any obligation to update or revise any forward-looking\nstatement, whether as a result of new information, future events and\ndevelopments or otherwise.\n\nABOUT DANAHER\nDanaher is a leading global life sciences and diagnostics innovator, committed\nto advancing the power of science and technology to improve human health.\nThrough our connected ecosystem of industry-leading businesses, we work side\nby side with customers to solve many of their most complex scientific and\nclinical challenges—accelerating the moment scientific discovery becomes\nhuman impact. Powered by the Danaher Business System, our advanced science and\ntechnology and proven ability to innovate help enable faster, more accurate\ndiagnoses and reduce the time, cost, and risk required to discover, develop,\nand deliver life-changing therapies. Through continuous improvement and\noperational excellence, our approximately 60,000 associates worldwide are\nfocused on delivering lasting impact and improving quality of life around the\nworld, while building a healthier, more sustainable tomorrow. That's\nInnovation at the speed of life. Explore more at www.danaher.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4796774-1&h=452825110&u=http%3A%2F%2Fwww.danaher.com%2F&a=www.danaher.com)\n.\n\nView original\ncontent:https://www.prnewswire.com/news-releases/danaher-collaborates-with-nvidia-to-advance-autonomous-science-302907891.html\n(https://www.prnewswire.com/news-releases/danaher-collaborates-with-nvidia-to-advance-autonomous-science-302907891.html)\n\nSOURCE Danaher Corporation\n\n\n\nInvestor: Rachel Vatnsdal, Vice President, Investor Relations, investor.relations@danaher.com; Media: Mary Kathryn Steel, Vice President, Corporate Communications, media@danaher.com; Danaher Corporate, 2200 Pennsylvania Avenue, N.W., Suite 800W, Washington, D.C. 20037, Telephone: (202) 828-0850\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-10-14T06:00:01.150979075Z","server_sent_at_ms":1791957601150},"received_at":"2026-10-14T06:00:01.201Z","source_url":"https://www.prnewswire.com/news-releases/danaher-collaborates-with-nvidia-to-advance-autonomous-science-302907891.html"},"analysis":{"id":"156661","press_release_id":"168393","analysis_json":{"industry":{"label":"Life Sciences Tools & Services","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Danaher announced a collaboration with NVIDIA to advance autonomous science, combining Danaher's instruments, automation and lab workflow software with NVIDIA accelerated computing and AI.\n\nInitial efforts focus on integrating AI into a select group of priority instruments using NVIDIA DGX Spark, RAPIDS, BioNeMo Open Models, Cosmos and Omniverse Digital Twins, with potential expansion across Danaher's broader portfolio.\n\nThe deal carries no disclosed financial terms or timelines; its significance is strategic, positioning Danaher's connected-science platform for AI-enabled laboratory workflows while preserving customer choice in models and technology providers.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Danaher pairs with NVIDIA to bring physical AI into the lab -- early-stage, no financial terms, but a strategic optics win for life-sciences tools."},"keyFigures":{"customDimensions":{}},"quotedText":"The next era of scientific discovery will be driven by a continuous loop between AI and experimentation","namedEntities":{"people":[{"name":"Julie Sawyer Montgomery","role":"CEO, Danaher"},{"name":"Kimberly Powell","role":"VP of Healthcare, NVIDIA"},{"name":"Rachel Vatnsdal","role":"VP Investor Relations, Danaher"},{"name":"Mary Kathryn Steel","role":"VP Corporate Communications, Danaher"}],"products":["NVIDIA DGX Spark","RAPIDS","BioNeMo Open Models","NVIDIA Cosmos world models","Omniverse Digital Twins"],"companies":[{"name":"Danaher Corporation","ticker":"DHR","relationship":"filer"},{"name":"NVIDIA","relationship":"partner"},{"name":"Masimo Corporation","relationship":"acquisition referenced in forward-looking statements"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Strategic AI collaboration with NVIDIA positions Danaher's instruments for AI-enabled workflows, but it is an early-stage, exploratory partnership with no financial terms, revenue commitments, or product timelines disclosed."},"tickerRelevance":{"others":[{"ticker":"NVDA","relevance":"partner"}],"primary":"DHR"},"globalImportance":35,"audienceRelevance":45,"eventTypeSecondary":["product_launch"],"importanceComponents":{"tickerTier":"mega-cap large-cap (DHR)","partnerTier":"NVDA halo effect","eventGravity":"exploratory partnership, no financial terms","householdBrandBoost":"moderate"}},"event_type":"partnership","event_type_secondary":["product_launch"],"sentiment":"bullish","material_impact_score":2,"narrative":"Danaher announced a collaboration with NVIDIA to advance autonomous science, combining Danaher's instruments, automation and lab workflow software with NVIDIA accelerated computing and AI.\n\nInitial efforts focus on integrating AI into a select group of priority instruments using NVIDIA DGX Spark, RAPIDS, BioNeMo Open Models, Cosmos and Omniverse Digital Twins, with potential expansion across Danaher's broader portfolio.\n\nThe deal carries no disclosed financial terms or timelines; its significance is strategic, positioning Danaher's connected-science platform for AI-enabled laboratory workflows while preserving customer choice in models and technology providers.","key_figures":{"customDimensions":{}},"named_entities":{"people":[{"name":"Julie Sawyer Montgomery","role":"CEO, Danaher"},{"name":"Kimberly Powell","role":"VP of Healthcare, NVIDIA"},{"name":"Rachel Vatnsdal","role":"VP Investor Relations, Danaher"},{"name":"Mary Kathryn Steel","role":"VP Corporate Communications, Danaher"}],"products":["NVIDIA DGX Spark","RAPIDS","BioNeMo Open Models","NVIDIA Cosmos world models","Omniverse Digital Twins"],"companies":[{"name":"Danaher Corporation","ticker":"DHR","relationship":"filer"},{"name":"NVIDIA","relationship":"partner"},{"name":"Masimo Corporation","relationship":"acquisition referenced in forward-looking statements"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T06:00:13.916Z","global_importance":35,"audience_relevance":45,"importance_components":{"tickerTier":"mega-cap large-cap (DHR)","partnerTier":"NVDA halo effect","eventGravity":"exploratory partnership, no financial terms","householdBrandBoost":"moderate"}},"durationMs":8877,"modelName":"glm-5.3-flashx"}}